Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies.

ABSTRACT: Platinum-based cancer therapy remains a cornerstone of first-line treatment for several solid tumours such as ovarian, testicular, and non-small cell lung cancers, where it has received regulatory approval as both monotherapy and combination regimens. However, the inevitable emergence of resistance has necessitated extensive preclinical and clinical efforts to develop rational platinum-based combinations. The most appealing candidates for combination therapy are those that offer additive and/or synergistic effects without undesirable overlapping toxicities. Whilst early strategies focussed on co-administration with cytotoxic chemotherapies, recent advances have shifted towards combinations with targeted therapies and immunotherapies, offering improved efficacy and durability of response. I

SUBMITTER: Yusoh NA 

PROVIDER: S-EPMC12167724 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature